BR112016029761A2 - composições antimicrobianas com agentes efervescentes - Google Patents

composições antimicrobianas com agentes efervescentes

Info

Publication number
BR112016029761A2
BR112016029761A2 BR112016029761A BR112016029761A BR112016029761A2 BR 112016029761 A2 BR112016029761 A2 BR 112016029761A2 BR 112016029761 A BR112016029761 A BR 112016029761A BR 112016029761 A BR112016029761 A BR 112016029761A BR 112016029761 A2 BR112016029761 A2 BR 112016029761A2
Authority
BR
Brazil
Prior art keywords
effervescent
compositions
antimicrobial compositions
treat
risk
Prior art date
Application number
BR112016029761A
Other languages
English (en)
Other versions
BR112016029761B1 (pt
BR112016029761A8 (pt
Inventor
Li Danping
Original Assignee
Melinta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54868661&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112016029761(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Melinta Therapeutics Inc filed Critical Melinta Therapeutics Inc
Publication of BR112016029761A2 publication Critical patent/BR112016029761A2/pt
Publication of BR112016029761A8 publication Critical patent/BR112016029761A8/pt
Publication of BR112016029761B1 publication Critical patent/BR112016029761B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Quinoline Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

a presente invenção refere-se a composições farmacêuticas compreendendo um derivado de ácido carboxílico de quinolona como agente antimicrobiano e um agente efervescente. estas composições têm tolerabilidade gastrointestinal melhorada e/ou potencial reduzido para causar efeitos colaterais gastrointestinais. estas composições são úteis para administração oral, para tratar, prevenir, ou reduzir o risco de infecções microbianas.
BR112016029761-0A 2014-06-20 2015-06-19 Composições compreendendo um derivado de ácido quinolona carboxílico e agentes efervescentes e uso das mesmas BR112016029761B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462014786P 2014-06-20 2014-06-20
US62/014,786 2014-06-20
PCT/US2015/036605 WO2015196027A1 (en) 2014-06-20 2015-06-19 Antimicrobial compositions with effervescent agents

Publications (3)

Publication Number Publication Date
BR112016029761A2 true BR112016029761A2 (pt) 2017-08-22
BR112016029761A8 BR112016029761A8 (pt) 2021-06-29
BR112016029761B1 BR112016029761B1 (pt) 2023-03-07

Family

ID=54868661

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016029761-0A BR112016029761B1 (pt) 2014-06-20 2015-06-19 Composições compreendendo um derivado de ácido quinolona carboxílico e agentes efervescentes e uso das mesmas

Country Status (31)

Country Link
US (2) US20150366857A1 (pt)
EP (3) EP3581180B1 (pt)
JP (2) JP6995479B2 (pt)
CN (2) CN114831955B (pt)
AR (1) AR100920A1 (pt)
AU (3) AU2015276954B2 (pt)
BR (1) BR112016029761B1 (pt)
CA (1) CA2952950C (pt)
CL (2) CL2016003273A1 (pt)
CR (2) CR20160592A (pt)
CY (2) CY1121995T1 (pt)
DK (2) DK3157510T3 (pt)
EA (1) EA034152B1 (pt)
EC (1) ECSP16095540A (pt)
ES (2) ES2732865T3 (pt)
HR (2) HRP20211685T1 (pt)
HU (2) HUE056298T2 (pt)
IL (1) IL249622A0 (pt)
LT (2) LT3581180T (pt)
MX (2) MX368940B (pt)
PE (2) PE20210927A1 (pt)
PH (1) PH12016502548A1 (pt)
PL (2) PL3157510T3 (pt)
PT (2) PT3581180T (pt)
RS (2) RS62538B1 (pt)
SI (2) SI3157510T1 (pt)
SV (1) SV2016005349A (pt)
TR (1) TR201909417T4 (pt)
TW (2) TWI705814B (pt)
UY (1) UY36184A (pt)
WO (1) WO2015196027A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022240897A1 (en) * 2021-05-10 2022-11-17 Sepelo Therapeutics, Llc Pharmaceutical composition comprising delafloxacin for administration into the lung

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194617A (en) * 1988-12-17 1993-03-16 Meiji Seika Kaisha, Ltd. 2,3-disubstituted-4-hydroxyquinoline derivatives
US5223264A (en) * 1989-10-02 1993-06-29 Cima Labs, Inc. Pediatric effervescent dosage form
GB9402203D0 (en) * 1994-02-04 1994-03-30 Smithkline Beecham Plc Pharmaceutical formulation
EP0992501B1 (en) 1995-09-22 2002-08-28 Wakunaga Pharmaceutical Co., Ltd. Pyridonecarboxylic acid derivatives as antibacterial agents
US6350470B1 (en) * 1998-04-29 2002-02-26 Cima Labs Inc. Effervescent drug delivery system for oral administration
DE19814256A1 (de) * 1998-03-31 1999-10-07 Asta Medica Ag Feste, schnellzerfallende Cetirizin-Formulierungen
EA004443B1 (ru) 1998-09-14 2004-04-29 Рэнбакси Лабораториз Лимитед Лекарственная форма для контролируемого высвобождения ципрофлоксацина для приема один раз в день
US6187317B1 (en) * 1999-07-14 2001-02-13 Judith Taylor Natural anti-diarrheal composition and method
US6414036B1 (en) * 1999-09-01 2002-07-02 Van Beek Global/Ninkov Llc Composition for treatment of infections of humans and animals
JP2005097116A (ja) 1999-11-11 2005-04-14 Wakunaga Pharmaceut Co Ltd キノリンカルボン酸誘導体アルカリ金属塩及びこれを用いたキノリンカルボン酸誘導体の精製法
US7157100B2 (en) * 2002-06-04 2007-01-02 J.B. Chemicals & Pharmaceuticals Ltd. Pharmaceutical composition for controlled drug delivery system
EP1789392A2 (en) 2004-07-30 2007-05-30 Abbott Laboratories Preparation of pyridonecarboxylic acid antibacterials
WO2006042034A2 (en) 2004-10-08 2006-04-20 Abbott Laboratories Salt and crystalline forms thereof of a drug
NZ555501A (en) * 2004-11-24 2010-01-29 Medpointe Healthcare Inc Compositions comprising azelastine and methods of use thereof
PT1868581E (pt) 2005-04-11 2012-06-22 Abbott Lab Composições farmacêuticas que possuem perfis de dissolução melhorados para fármacos pouco solúveis
EP1745775B1 (en) 2005-07-19 2008-05-28 Ethypharm Gastroretentive formulations and manufacturing process thereof.
US7611739B2 (en) 2006-01-06 2009-11-03 Amerilab Technologies, Inc. Method of using guava extract and composition including guava extract
US7892447B2 (en) * 2006-08-11 2011-02-22 Aqua Resources Corporation Nanoplatelet metal hydroxides and methods of preparing same
CN1943561A (zh) * 2006-08-23 2007-04-11 北京阜康仁生物制药科技有限公司 普卢利沙星口腔崩解片及其制备方法
HUE046465T2 (hu) 2006-12-22 2020-03-30 Ironwood Pharmaceuticals Inc Epesavat megkötõ anyagokat tartalmazó készítmények nyelõcsõ-rendellenességek kezelésére
NZ580972A (en) * 2007-06-04 2012-02-24 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
MY194407A (en) * 2008-11-15 2022-11-30 Melinta Subsidiary Corp Antimicrobial Compositions
WO2010096551A2 (en) * 2009-02-18 2010-08-26 Rib-X Pharmaceuticals, Inc. Antimicrobial compositions
GB201020076D0 (en) * 2010-11-26 2011-01-12 Liverpool School Tropical Medicine Antimalarial compounds
ES2637113T3 (es) * 2011-01-10 2017-10-10 Infinity Pharmaceuticals, Inc. Procedimientos para preparar isoquinolinonas y formas sólidas de isoquinolinonas
BR112013017985B1 (pt) * 2011-01-14 2021-06-29 Spero Therapeutics Inc. Formas sólidas de inibidor de girase (r)-1-etil-3-[6-flúor-5-[2-(1-hidróxi-1-metil-etil)pirimidin- 5-il]-7-(tetra-hidrofuran-2-il)-1h-benzimidazol-2-il]ureia, seu sal de ácido clorídrico, método de preparação das mesmas e composição farmacêutica que os compreende
JP2013034468A (ja) * 2011-08-10 2013-02-21 Nisshin Sugar Mfg Co Ltd 発泡成型甘味料
WO2013090893A1 (en) * 2011-12-16 2013-06-20 Celanese Eva Performance Polymers, Inc. Gastroretentive controlled release vehicles that include ethylene copolymers, ethyl celluloses, and/or thermpoplastic polyurethanes
CN102697751A (zh) * 2012-05-30 2012-10-03 河南牧翔动物药业有限公司 一种畜禽专用恩诺沙星泡腾分散片及其制备方法

Also Published As

Publication number Publication date
PL3157510T3 (pl) 2019-12-31
RS59064B1 (sr) 2019-08-30
NZ727638A (en) 2023-08-25
CA2952950C (en) 2023-11-14
MX368940B (es) 2019-10-21
EP3157510A1 (en) 2017-04-26
AU2015276954A1 (en) 2017-01-12
CN114831955B (zh) 2024-03-12
SI3157510T1 (sl) 2019-09-30
CN106572982B9 (zh) 2022-07-08
DK3581180T3 (da) 2021-11-08
JP2020183415A (ja) 2020-11-12
CR20160592A (es) 2017-02-21
TW201625249A (zh) 2016-07-16
EP3581180A1 (en) 2019-12-18
ES2897576T3 (es) 2022-03-01
PL3581180T3 (pl) 2022-02-07
AU2020256457B2 (en) 2021-09-30
RS62538B1 (sr) 2021-12-31
DK3157510T3 (da) 2019-07-01
SI3581180T1 (sl) 2021-12-31
UY36184A (es) 2016-01-29
US20150366857A1 (en) 2015-12-24
MX2019012608A (es) 2019-12-02
CL2020003153A1 (es) 2021-06-25
CA2952950A1 (en) 2015-12-23
EP3157510A4 (en) 2018-02-21
ES2732865T3 (es) 2019-11-26
CY1121995T1 (el) 2020-10-14
EA201692532A1 (ru) 2017-05-31
EP3919057A1 (en) 2021-12-08
EA034152B1 (ru) 2020-01-09
AU2015276954B2 (en) 2020-07-23
JP6995479B2 (ja) 2022-01-14
CY1125395T1 (el) 2023-03-24
HRP20191133T1 (hr) 2019-09-20
PT3581180T (pt) 2021-11-09
SV2016005349A (es) 2017-08-31
ECSP16095540A (es) 2017-03-31
CN106572982A (zh) 2017-04-19
HRP20211685T1 (hr) 2022-02-04
AU2021286284A1 (en) 2022-01-06
AU2021286284B2 (en) 2024-02-29
MX2016017350A (es) 2017-04-06
CR20200565A (es) 2021-01-14
HUE056298T2 (hu) 2022-02-28
HUE044764T2 (hu) 2019-11-28
PE20210927A1 (es) 2021-05-19
IL249622A0 (en) 2017-02-28
TWI732337B (zh) 2021-07-01
EP3157510B1 (en) 2019-03-27
EP3581180B1 (en) 2021-08-04
AU2020256457A1 (en) 2020-11-12
CN106572982B (zh) 2022-06-03
TWI705814B (zh) 2020-10-01
CN114831955A (zh) 2022-08-02
JP7149991B2 (ja) 2022-10-07
BR112016029761B1 (pt) 2023-03-07
WO2015196027A1 (en) 2015-12-23
CL2016003273A1 (es) 2017-08-04
JP2017518349A (ja) 2017-07-06
US20200237744A1 (en) 2020-07-30
BR112016029761A8 (pt) 2021-06-29
LT3581180T (lt) 2021-12-27
TW202005650A (zh) 2020-02-01
PT3157510T (pt) 2019-06-21
PE20170304A1 (es) 2017-04-19
TR201909417T4 (tr) 2019-07-22
LT3157510T (lt) 2019-09-25
PH12016502548A1 (en) 2017-04-10
AR100920A1 (es) 2016-11-09

Similar Documents

Publication Publication Date Title
CY1123189T1 (el) Αντιμικροβiακο πεπτιδιο
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
PH12015502013B1 (en) Pharmaceutical composition of s-ketamine hydrochloride
PH12015501957A1 (en) Pharmaceutical composition of s-ketamine hydrochloride
PH12016501988A1 (en) Antibacterial compounds
BR112016024235A2 (pt) composições farmacêuticas compreendendo agentes antibacterianos
CL2020003153A1 (es) Composiciones antimicrobianas con agentes efervescentes (divisional de solicitud n° 03273-2016)
BR112018007374A2 (pt) composição farmacêutica
EA201270547A1 (ru) Фармацевтическая композиция
MX360040B (es) Nuevo agente antibacteriano derivado de florfenicol unido a sulfoximina y el uso del mismo en el tratamiento de infecciones bacterianas en ganado vacuno.
PH12016502547A1 (en) Methods for treating infections
BR112016024236A2 (pt) composições farmacêuticas compreendendo agentes antibacterianos
IN2014KN02584A (pt)
MX2019007390A (es) Peptidos antimicrobianos y usos de los mismos.
UA108238C2 (xx) Антибактеріальна композиція
EA201390764A1 (ru) Фармацевтические композиции

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: MELINTA SUBSIDIARY CORP. (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25G Requested change of headquarter approved

Owner name: MELINTA SUBSIDIARY CORP. (US)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/06/2015, OBSERVADAS AS CONDICOES LEGAIS